Description
Product details
Telmaheal Beta 25 – Telmisartan & Metoprolol Succinate Tablets Blood Pressure & Cardiovascular Management Telmaheal Beta 25 is a combination cardiovascular medicine containing Telmisartan and Metoprolol Succinate. The two ingredients work differently: Telmisartan helps relax blood vessels, while Metoprolol Succinate reduces excessive stimulation of the heart. Together, they may provide better blood-pressure control in selected patients when combination therapy is clinically appropriate. Why Is This Combination Important? High blood pressure often has more than one contributing mechanism. For some patients, controlling vascular resistance alone may not provide the desired response. Telmaheal Beta combines an ARB with a beta blocker, allowing treatment to act on both blood vessels and cardiac activity. Possible Side Effects Some patients may experience: Dizziness Tiredness Headache Slow heartbeat Low blood pressure Weakness Cold hands or feet Nausea or stomach discomfort Important Symptoms Medical attention may be required for: Very slow heart rate Fainting Severe dizziness Significant breathing difficulty New or worsening heart-failure symptoms Marked fall in blood pressure Symptoms associated with high potassium levels Serious allergic reactions Pregnancy Safety Telmisartan acts on the renin-angiotensin system and can cause serious fetal harm. Therefore, Telmisartan-containing medicines should not be used during pregnancy. A patient who becomes pregnant while receiving treatment should contact the treating healthcare professional promptly. Important Medicine Interactions Extra attention may be required with: Other blood-pressure-lowering medicines Medicines that reduce heart rate Certain calcium-channel blockers Digoxin Potassium supplements Potassium-containing salt substitutes Certain diuretics NSAID painkillers Lithium Safety Information for Patients Telmaheal Beta 25 should be used under medical supervision. Patients should not independently change the dose because of a single high or low blood-pressure reading. Special attention is needed if there is persistent dizziness, fainting, unusually slow pulse, breathing difficulty, significant weakness, swelling, or worsening cardiovascular symptoms. The medicine should be taken according to the prescribed schedule, and regular follow-up remains important even when blood pressure appears controlled. Frequently Asked Questions 1. What is Telmaheal Beta 25 used for? It may be prescribed for hypertension and other appropriate cardiovascular situations where both Telmisartan and Metoprolol are clinically required. 2. How does Telmaheal Beta 25 control blood pressure? Telmisartan relaxes blood vessels by blocking angiotensin II activity, while Metoprolol reduces excessive beta-1 stimulation of the heart. 3. Can Telmaheal Beta 25 reduce heart rate? Yes. Metoprolol can slow the heart rate as part of its therapeutic action. 4. Why should potassium be monitored? Telmisartan can increase potassium levels, particularly in patients with kidney impairment or those taking other potassium-raising medicines. 5. Can this medicine cause dizziness? Yes. Dizziness may occur if blood pressure falls, particularly when starting or adjusting treatment.
